KRAS and non-small cell lung carcinoma: The findings indicated that reducing the expression of Mad2 through siRNA could overcome drug resistance and enhance the responsiveness of lung cancer cells to cisplatin while causing minimal toxicity.613 Mutation of the Kirsten ras sarcoma viral oncogene homolog (KRAS) is also commonly seen in NSCLC.